<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1130</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15843530</PubmedId>
            <Abstract>We have used intracellular cytokine staining and MHC class I tetramer binding in conjunction with granzyme B protease expression and in vivo BrdU uptake to characterize the primary murine CD8(+) T cell response to pulmonary influenza virus infection. We have observed that the majority (&gt;90%) of the CD8(+) T cell response to the A/Japan/305/57 virus in the lung at the peak of the response (days 9-11) is directed to four epitopes (three dominant and one subdominant). Using induction of granzyme B as a surrogate to identify specific activated CD8(+) T cells, we found that an unexpectedly large fraction ( approximately 70%) of lung-infiltrating CD8(+) T cells expressed granzyme B on day 6 of infection when estimates by MHC tetramer/intracellular cytokine staining yielded substantially lower frequencies ( approximately 30%). In addition, by using intranasal administration of BrdU during infection, we obtained evidence for proliferative expansion of activated CD8(+) T cells in the infected lung early (days 5-7) in the primary response. These results suggest that the frequency and number of specific CTL present in the lung early in infection may be underestimated by standard detection methods, and primary CD8(+) T cell expansion may occur in both secondary lymphoid organs and the infected lung.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>5332-40</ArticlePages>
            <ArticleTitle>Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Lawrence</LastName>
                    <ForeName>Christopher W</ForeName>
                </Author>
                <Author>
                    <LastName>Ream</LastName>
                    <ForeName>Rebecca M</ForeName>
                </Author>
                <Author>
                    <LastName>Braciale</LastName>
                    <ForeName>Thomas J</ForeName>
                </Author>
            </Authors>
            <Affiliations>Beirne B. Carter Center for Immunology Research and Department of Microbiology, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA.</Affiliations>
            <ArticleChemicalList>Cytokines;Epitopes, T-Lymphocyte;Granzymes;Gzmb protein, mouse;Serine Endopeptidases</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; CD8-Positive T-Lymphocytes(enzymology; immunology; pathology; virology); Cell Movement(immunology); Cell Proliferation; Cytokines(biosynthesis); Epitopes, T-Lymphocyte(immunology); Female; Granzymes; Influenza A virus(immunology); Lung(enzymology; immunology; pathology; virology); Lymph Nodes(immunology; pathology; virology); Lymphocyte Count; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections(immunology; pathology; virology); Pneumonia, Viral(immunology; pathology; virology); Serine Endopeptidases(biosynthesis); Virus Replication(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>174</Volume>
                <Issue>9</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HA 204-212</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LYQNVGTYV</LinearSequence>
                        <StartingPosition>204</StartingPosition>
                        <EndingPosition>212</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03451.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>387161</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table I</LocationOfData>
                <EpitopeId>40910</EpitopeId>
                <ReferenceStartingPosition>204</ReferenceStartingPosition>
                <ReferenceEndingPosition>212</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>16175</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-11 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:8469</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>387161</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 sub-lethal dose of 3953 TCID50.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mouse adapted source species was used for innoculation.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Bronchial Aveolar Lavage (BAL)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 204-212</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LYQNVGTYV</LinearSequence>
                                        <StartingPosition>204</StartingPosition>
                                        <EndingPosition>212</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>387161</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope specific IFN-g+ CD8+ cells are first detected at day 5 post primary infection and peak at ~18% at day 9. Similar results are seen in BAL and lung parenchyma CD8+ cells. Peptide-tetramer staining gives similar results, although with slightly delayed kinetics. The total anti-source species response is shown to be mainly (&gt;90%) due to the responses to this and 3 other epitopes, which have similar kinetics of activation and contraction. The complete clearance of virus at day 9 suggests that virus specific T-cells are being underestimated by this analysis. The frequency of granzyme-B+ cells and of BrdU incorporating cells in the lung are shown to better correlate with the infection kinetics, with 70% of lung CD8+ cells expressing granzyme at day 6 post infection. This high frequency cannot be accounted for by the accumulation of T cells derived form the draining lymph node, and evidence for early phase proliferation of CD8+ cells in the infected lungs was obtained by BrdU CD8+ uptake in the lungs.  IFN-g positive cells were determined after 6h culture with peptide and source species infected APCS, in the presence of 100 U/ml IL-2.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HA 529-537</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IYATVAGSL</LinearSequence>
                        <StartingPosition>529</StartingPosition>
                        <EndingPosition>537</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03451.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>387161</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table I</LocationOfData>
                <EpitopeId>29560</EpitopeId>
                <ReferenceStartingPosition>529</ReferenceStartingPosition>
                <ReferenceEndingPosition>537</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>16176</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-11 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:8469</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>387161</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 sub-lethal dose of 3953 TCID50.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mouse adapted source species was used for innoculation.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Bronchial Aveolar Lavage (BAL)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 529-537</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IYATVAGSL</LinearSequence>
                                        <StartingPosition>529</StartingPosition>
                                        <EndingPosition>537</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>387161</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope specific IFN-g+ CD8+ cells are first detected at day 5 post primary infection and peak at ~15% at day 9. Similar results are seen in BAL and lung parenchyma CD8+ cells. Peptide-tetramer staining gives similar results, although with slightly delayed kinetics. The total anti-source species response is shown to be mainly (&gt;90%) due to the responses to this and 3 other  epitopes, which have similar kinetics of activation and contraction. The complete clearance of virus at day 9 suggests that virus specific T-cells are being underestimated by this analysis. The frequency of granzyme-B+ cells and of BrdU incorporating cells in the lung are shown to better correlate with the infection kinetics, with 70% of lung CD8+ cells expressing granzyme at day 6 post infection. This high frequency cannot be accounted for by the accumulation of T cells derived form the draining lymph node, and evidence for early phase proliferation of CD8+ cells in the infected lungs was obtained by BrdU CD8+ uptake in the lungs.  IFN-g positive cells were determined after 6h culture with peptide and source species infected APCS, in the presence of 100 U/ml IL-2.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HA 210-219</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TYVSVGTST</LinearSequence>
                        <StartingPosition>210</StartingPosition>
                        <EndingPosition>218</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03451.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>387161</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table I</LocationOfData>
                <EpitopeId>67499</EpitopeId>
                <ReferenceStartingPosition>529</ReferenceStartingPosition>
                <ReferenceEndingPosition>537</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>16177</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-11 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:8469</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>387161</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 sub-lethal dose of 3953 TCID50.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mouse adapted source species was used for innoculation.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Bronchial Aveolar Lavage (BAL)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 210-219</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYVSVGTST</LinearSequence>
                                        <StartingPosition>210</StartingPosition>
                                        <EndingPosition>218</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>387161</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Subdominant epitope specific IFN-g+ CD8+ cells are first detected at day 5 post primary infection and peak at &lt;5% at day 9. Similar results are seen in BAL and lung parenchyma CD8+ cells. Peptide-tetramer staining gives similar results. The total anti-source species response is shown to be mainly (&gt;90%) due to the responses to this and 3 other epitopes, which have similar kinetics of activation and contraction. The complete clearance of virus at day 9 suggests that virus specific T-cells are being underestimated by this analysis. The frequency of granzyme-B+ cells and of BrdU incorporating cells in the lung are shown to better correlate with the infection kinetics, with 70% of lung CD8+ cells expressing granzyme at day 6 post infection. This high frequency cannot be accounted for by the accumulation of T cells derived form the draining lymph node, and evidence for early phase proliferation of CD8+ cells in the infected lungs was obtained by BrdU CD8+ uptake in the lungs.  IFN-g positive cells were determined after 6h culture with peptide and source species infected APCS, in the presence of 100 U/ml IL-2.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP147-155</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TYQRTRALV</LinearSequence>
                        <StartingPosition>147</StartingPosition>
                        <EndingPosition>155</EndingPosition>
                        <SourceMolecule>
                            <IedbAccession>SRC124</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>387161</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table I</LocationOfData>
                <EpitopeId>67436</EpitopeId>
                <ReferenceStartingPosition>147</ReferenceStartingPosition>
                <ReferenceEndingPosition>155</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Swiss-prot ID corresponds to Puerto Rico 8/34 strain, harboring this widely conserved immunodominant epitope.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>16178</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-11 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:8469</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>387161</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1 sub-lethal dose of 3953 TCID50.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mouse adapted source species was used for innoculation.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Bronchial Aveolar Lavage (BAL)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP147-155</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYQRTRALV</LinearSequence>
                                        <StartingPosition>147</StartingPosition>
                                        <EndingPosition>155</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC124</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>387161</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope specific IFN-g+ CD8+ cells are first detected at day 5 post primary infection and peak at ~25% at day 9. Similar results are seen in BAL and lung parenchyma CD8+ cells. Peptide-tetramer staining gives similar results, although with slightly delayed kinetics. The total anti-source species response is shown to be mainly (&gt;90%) due to the responses to this and 3 other epitopes, which have similar kinetics of activation and contraction. The complete clearance of virus at day 9 suggests that virus specific T-cells are being underestimated by this analysis. The frequency of granzyme-B+ cells and of BrdU incorporating cells in the lung are shown to better correlate with the infection kinetics, with 70% of lung CD8+ cells expressing granzyme at day 6 post infection. This high frequency cannot be accounted for by the accumulation of T cells derived form the draining lymph node, and evidence for early phase proliferation of CD8+ cells in the infected lungs was obtained by BrdU CD8+ uptake in the lungs.  IFN-g positive cells were determined after 6h culture with peptide and source species infected APCS, in the presence of 100 U/ml IL-2.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

